New antibody aims to neutralize allergies by clearing IgE
Disease control
Recruiting now
This early-stage trial tests an experimental antibody drug called LCA-0061, designed to target and remove immunoglobulin E (IgE), a key driver of allergic reactions. The study first evaluates safety and tolerability in healthy people with elevated IgE levels, then in people with …
Phase: PHASE1 • Sponsor: Lycia Therapeutics, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC